Terms: = Germ cell tumor AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Clinical Outcome
23 results:
1. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
[TBL] [Abstract] [Full Text] [Related]
2. Immune correlates of clinical outcome in melanoma.
Pawelec G
Immunology; 2018 Apr; 153(4):415-422. PubMed ID: 29164593
[TBL] [Abstract] [Full Text] [Related]
3. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence clinical outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
Erbe AK; Wang W; Carmichael L; Kim K; Mendonça EA; Song Y; Hess D; Reville PK; London WB; Naranjo A; Hank JA; Diccianni MB; Reisfeld RA; Gillies SD; Matthay KK; Cohn SL; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Gilman AL; Yu AL; Sondel PM
Clin Cancer Res; 2018 Jan; 24(1):189-196. PubMed ID: 28972044
[No Abstract] [Full Text] [Related]
4. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
5. Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.
Najjar YG; Ding F; Lin Y; VanderWeele R; Butterfield LH; Tarhini AA
J Transl Med; 2017 Feb; 15(1):39. PubMed ID: 28222797
[TBL] [Abstract] [Full Text] [Related]
6. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract] [Full Text] [Related]
7. il-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.
Sim GC; Martin-Orozco N; Jin L; Yang Y; Wu S; Washington E; Sanders D; Lacey C; Wang Y; Vence L; Hwu P; Radvanyi L
J Clin Invest; 2014 Jan; 124(1):99-110. PubMed ID: 24292706
[TBL] [Abstract] [Full Text] [Related]
8. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Ridolfi L; Petrini M; Granato AM; Gentilcore G; Simeone E; Ascierto PA; Pancisi E; Ancarani V; Fiammenghi L; Guidoboni M; de Rosa F; Valmorri L; Scarpi E; Nicoletti SV; Baravelli S; Riccobon A; Ridolfi R
J Transl Med; 2013 May; 11():135. PubMed ID: 23725550
[TBL] [Abstract] [Full Text] [Related]
9. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
[TBL] [Abstract] [Full Text] [Related]
10. Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.
Gunturu KS; Meehan KR; Mackenzie TA; Crocenzi TS; McDermott D; Usherwood EJ; Margolin KA; Crosby NA; Atkins MB; Turk MJ; Ahonen C; Fuse S; Clark JI; Fisher JL; Noelle RJ; Ernstoff MS
J Clin Oncol; 2010 Mar; 28(7):1196-202. PubMed ID: 20124177
[TBL] [Abstract] [Full Text] [Related]
11. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
[TBL] [Abstract] [Full Text] [Related]
12. Depletion of normal B cells with rituximab as an adjunct to il-2 therapy for renal cell carcinoma and melanoma.
Aklilu M; Stadler WM; Markiewicz M; Vogelzang NJ; Mahowald M; Johnson M; Gajewski TF
Ann Oncol; 2004 Jul; 15(7):1109-14. PubMed ID: 15205206
[TBL] [Abstract] [Full Text] [Related]
13. S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma.
Schmidt H; Sorensen BS; Nexo E; von der Maase H
Melanoma Res; 2004 Jun; 14(3):211-5. PubMed ID: 15179191
[TBL] [Abstract] [Full Text] [Related]
14. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.
Labarrière N; Pandolfino MC; Gervois N; Khammari A; Tessier MH; Dréno B; Jotereau F
Cancer Immunol Immunother; 2002 Nov; 51(10):532-8. PubMed ID: 12384804
[TBL] [Abstract] [Full Text] [Related]
15. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness.
Mocellin S; Ohnmacht GA; Wang E; Marincola FM
Int J Cancer; 2001 Jul; 93(2):236-42. PubMed ID: 11410872
[TBL] [Abstract] [Full Text] [Related]
16. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients.
Bernengo MG; Quaglino P; Cappello N; Lisa F; Osella-Abate S; Fierro MT
Melanoma Res; 2000 Feb; 10(1):55-65. PubMed ID: 10711641
[TBL] [Abstract] [Full Text] [Related]
17. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes.
Maraveyas A; Baban B; Kennard D; Rook GA; Westby M; Grange JM; Lydyard P; Stanford JL; Jones M; Selby P; Dalgleish AG
Ann Oncol; 1999 Jul; 10(7):817-24. PubMed ID: 10470429
[TBL] [Abstract] [Full Text] [Related]
18. il-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma.
Bowman L; Grossmann M; Rill D; Brown M; Zhong WY; Alexander B; Leimig T; Coustan-Smith E; Campana D; Jenkins J; Woods D; Kitchingman G; Vanin E; Brenner M
Blood; 1998 Sep; 92(6):1941-9. PubMed ID: 9731051
[TBL] [Abstract] [Full Text] [Related]
19. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
[TBL] [Abstract] [Full Text] [Related]
20. clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.
Borrione P; Montacchini L; Beggiato E; Pileri A; Bianchi A; Massaia M
Leuk Lymphoma; 1996 Apr; 21(3-4):325-30. PubMed ID: 8726415
[TBL] [Abstract] [Full Text] [Related]
[Next]
